Gentis is a biomaterials and orthopedics company that has developed and is testing a breakthrough, non-fusion technology for the treatment of spinal disc disease. The company’s lead product, DiscCell, is a radio-opaque implant designed to restore normal biomechanical function of a degenerated or surgically treated intervertebral disc by augmenting or replacing the worn-out gel-like tissue at its center (the nucleus pulposus). This treatment is intended to delay further degradation of the diseased disc and to reduce pain. If successful, the product has the potential to obviate the need for more invasive surgeries, leading to a better quality of life for patients.
The company ceased operations in 2016.
© 2021 Pappas Capital, LLC. ALL RIGHTS RESERVED.